

Georgia Department of Public Health: GDPH Office Hours for ALF and PCH January 26, 2024

Meet the Team



Presenters:

Erica Umeakunne, MSN, MPH, APRN, CIC

Infection Prevention Specialist Alliant Health Solutions

JoAnna M. Wagner, MSN, RN, BHSA, CIC

Director/Nurse Epidemiologist Healthcare-Associated Infections Antimicrobial Resistance Program Georgia Department of Public Health



Erica Umeakunne, MSN, MPH, APRN, CIC

Infection Prevention Specialist Alliant Health Solutions

Erica Umeakunne is an adult gerontology nurse practitioner and infection preventionist with experience in primary care, critical care, health care administration, and public health.

She was previously the interim hospital epidemiology director for a large health care system in Atlanta and a nurse consultant in the Center for Disease Control and Prevention's (CDC) Division of Healthcare Quality Promotion. While at the CDC, she served as an infection prevention and control (IPC) subject matter expert for domestic and international IPC initiatives and emergency responses, including Ebola outbreaks and, most recently, the COVID-19 pandemic.

Erica enjoys reading, traveling, family time, and outdoor activities.

Contact: Erica.Umeakunne@allianthealth.org





JoAnna Wagner, MSN, RN, BHSA, CIC

Director, Healthcare-Associated Infections Antimicrobial Resistance Program Georgia Department of Public Health

JoAnna has been with the Georgia Department of Public Health since 2016 and currently serves as the director of the Healthcare-Associated Infections Antimicrobial Resistance (HAI AR) Program for the Acute Disease and Epidemiology Section. Her leadership supports an HAI AR analytics team, an infection prevention team, and an antimicrobial stewardship team. She has been a nurse for 24 years and worked as an infection preventionist for 20 years.





Thank You to Our Partners

- Georgia Department of Public Health
- University of Georgia






UNIVERSITY OF GEORGIA



Objectives

- Provide updates on COVID-19 epidemiology and associated indicators
- Review COVID-19 metrics that help inform infection prevention and control (IPC) recommendations
- Discuss Candida auris epidemiology and implications for congregate living settings
- Share resources to support COVID-19 IPC activities
- Address any facility-specific IPC questions or concerns





COVID-19 Update









CDC COVID-19 Data Tracker

COVID-19 Update for the United States

Early Indicators

•			
Test Positivity >	Emergency Department Visits >	Hospitalizations >	Deaths >
% Test Positivity	% Diagnosed as COVID-19	Hospital Admissions	% of All Deaths in U.S. Due to COVID-19
11.8%	2.5%	32,861	4.3%
(January 7 to January 13, 2024)	(January 7 to January 13, 2024)	(January 7 to January 13, 2024)	(January 7 to January 13, 2024)
Trend in % Test Positivity	Trend in % Emergency Department Visits	Trend in Hospital Admissions	Trend in % COVID-19 Deaths
-1% in most recent week	-19% in most recent week	-9.6% in most recent week	+10.3% in most recent week
Nov 25, 2023 Jan 13, 2024	Nov 25, 2023 Jan 13, 2024	Nov 25, 2023 Jan 13, 2024	Nov 25, 2023 Jan 13, 2024
These early indicators represent	a portion of national COVID-19 tests and	Total Hospitalizations	Total Deaths
emergency department visits. <u>Wa</u> of spread.	astewater information also provides early indicators	6,727,163	1,169,666
CDC Test Positiv	vity data through: January 13, 2024; Emergency Department Visit o	data through: January 13, 2024; Hospitalization data thr	rough: January 13, 2024; Death data through: January 13, 2024

Severity Indicators


Posted: January 19, 2024 12:00 PM ET



	COVID-19 hospital adm Based on new COVID-19 hosp		
	Total	Percent	% Change
≥ 20.0	146	4.53%	-3.29%
10.0 - 19.9	1054	32.71%	-5.34%
<10.0	2022	62.76%	8.63%

Time Period: New COVID-19 hospital admissions per 100,000 population (7-day total) are calculated using data from the MMWR week (Sun-Sat) ending January 13, 2024.

Reported COVID-19 New Hospital Admissions Rate per 100,000 Population in the Past Week, by County – United States






View Maps > of Hospitalizations, Deaths, Emergency Department Visits, and Test Positivity

https://covid.cdc.gov/coviddata-tracker/#cases_newadmissions-rate-county





https://covid.cdc.gov/covid-datatracker/#cases_new-admissionspercent-change-county

Insufficient data




Wastewater Surveillance

Current virus levels in wastewater by site

This metric shows whether SARS-CoV-2 levels at a site are currently higher or lower than past historical levels at the same site. 0% means levels are the lowest they have been at the site; 100% means levels are the highest they have been at the site. Public health officials watch for increasing levels of the virus in wastewater over time and use these data to help make public health decisions.

A Note: Sites began collecting data at different times. Sites that began reporting wastewater data after December 1, 2021 are not comparable to sites that started reporting data on or before December 1, 2021. The data history for these new sites is not long enough to reflect the same surges as the other sites.



I Г	_	C 11			
L L			-	-	

Current virus

levels category

New Site	0	0	N/A**	
0% to 19%	0	0	N/A**	
20% to 39%	0	0	- 100%	
40% to 59%	0	0	N/A**	
60% to 79%	7	41	- 30%	
80% to 100%	10	59	- 9%	

Current SARS-CoV-2 virus levels by site, Georgia

Num.

sites

Category change

sites in last 7 days

Total sites with current data: 17 Total number of wastewater sampling sites: 27 How is the current SARS-CoV-2 level compared to past

levels calculated?

https://covid.cdc.gov/covid-datatracker/#wastewater-surveillance

Select legend categories to filter points on the map.

O New site • 0% to 19% 20% to 39% 40% to 59% 60% to 79% 80% to 100% No recent data




Weighted and Nowcast Estimates in United States for 2-Week Periods in 10/1/2023 – 1/20/2024

Hover over (or tap in mobile) any lineage of interest to see the amount of uncertainty in that lineage's estimate.

କ


Nowcast Estimates in United States for 1/7/2024 - 1/20/2024

Weighted Estimates: Variant proportions based on reported genomic sequencing results 100% % Viral Lineages Among Infections 80% 60% 83 835 BGS 40% N. 835 835 ¥ N 20% H ¥ R 0% 0/14/23 11/25/23 10/28/23 11/11/23 12/9/23 2/23/23 1/6/24 Collection date, two-week period ending




SARS-CoV-2 Variant Surveillance

https://covid.cdc.gov/cov id-data-tracker/#variantproportions





Safety Strategy



Candida auris in Georgia Essential Information for Preparedness and Response

Alliant DPH Strike Team Office Hours Presentation for ALFs/PCHs

JoAnna Wagner, MSN, RN, CIC, Director, Healthcare-Associated Infections Antimicrobial Resistance Program

January 26, 2024



Who We Are

- Georgia Department of Public Health
- Team of experienced infection preventionists
- Offer free, non-regulatory infection prevention consultation
- Conduct consults and on-site or virtual walk-throughs
- Provide infection prevention support, resources and recommendations for health care facilities

Contact us at hai@dph.ga.gov

Candida auris (C. auris): Why Are We Concerned?

- CDC identified as an urgent public health threat in 2019
- Highly drug-resistant = limited/no treatment options for infections
- Spreads easily in health care settings
- Colonization can lead to infections
- Identification can be challenging



Highly drug-resistant

Patients can become colonized and develop invasive infections




Spreads in health care settings

Background

- First case of C. auris in Georgia was identified in 2019
- What is the state DPH doing?
 - Investigating reports of C. auris
 - Conducting point prevalence surveys with ARLN support
 - Teaching health care staff how to prevent and control C. auris infection and spread
 - Adding to the Notifiable Disease List
 - Requesting isolate submission to GPHL for suspected or confirmed cases
 - Performing Infection Control Assessments and Response (ICAR) and observing infection prevention practices at health care facilities for response and prevention

Increasing Cases in Georgia July 2019–December 4, 2023




*data are preliminary and subject to change

C. auris Case Demographics


n = 408					
Gender (%)		Ethnicity			
Male	61	Non-Hispanic	355		
Female	39	Hispanic	13		
		Unknown	39		
Age (Count of Specimen Source)		Race			
5-24	12	Black	230		
25-49	70	White	138		
50-65	141	Asian	5		
65+	185	Unknown	28		
		Other	6		
		American Indian/Alaska	1		
Facility Type (Count of Specimen Source)					
Acute Care Hospital	198				
Ventilator-Capable Skilled Nursing Facility	63				
Skilled Nursing Facility	15				
Long-term Acute Care Hospital	128				
Other (Rehab Facility, Renal Care)	4				

Increasing Clinical Cases

- 408 cases since July 2019**
- 184 clinical cases and 224 screening
- Fulton County has had the most cases, followed by Richmond and Miller counties
- *Clinical Cases increasing:
 - Q4 2023 40 (as of December 4th)
 - Q3 2023 53
 - Q2 2023 44
 - Q1 2023 19
 - *2023: 156 cases as of Dec 4th
- 2022: 15 cases



Increasing Transmission of C. auris in the U.S.




Typically Affects the Sickest of the Sick

- Tracheostomies
- Ventilator-dependent
- Multiple health care encounters
- Colonized with other multidrugresistant organisms
- Recently received antibiotics
 and antifungals
- Not a threat to the general public or healthy individuals



vSNFs and LTACHs Are Disproportionately Affected



Pacilli, et al. Clin Infect Dis. 2020 Dec 31;71(11):e718-e725.


vSNF = skilled nursing facility with ventilator units; LTACH = long-term acute care hospital; SNF = skilled nursing facility; ACH = short-stay acute care hospital

Patients Are Often Colonized Indefinitely

- Primarily on skin
 - Nares and other body sites can also become colonized
 - Recommend screening by swabbing the axilla/groin
- Persistent for many months
- No currently known decolonization strategies
- Can lead to:
 - Transmission to others
 - Invasive infection

Can Cause Invasive Infections and High Mortality

5-10% of colonized patients develop bloodstream infections




Mortality of invasive infections is ~40% within the first 30 days

Adams E, Quinn M, Tsay S, et al. Candida auris in Healthcare Facilities, New York, USA, 2013–2017. Emerg Infect Dis. 2018;24(10):1816-1824.

C. auris Persists in the Environment

- Can survive over a month
- Some common disinfectants (quaternary ammonia compounds) don't work



C. auris Is Frequently Transmitted via Shared Mobile Equipment That Is Not Properly Cleaned and Disinfected Between Patients/Residents



Early Detection and Containment

Identifying C. auris Cases Has Been Challenging

- Misidentification by different diagnostic methods
- Yeast not identified to species level
 - Yeast from urine is usually tossed out because not considered an infection
 - Only about 50% of clinical cases are from blood
- Missed detection of colonization cases without screening


Early Detection Is Key to Controlling Spread


- Earlier detection allows for earlier infection control precautions
- Strategies for early identification
 - Species identification of all Candida specimens
 - Screening high-risk patients*
 - Periodic point prevalence surveys in high-risk facilities, even those without known cases



*From facilities/areas with high C. auris burden or outbreaks, health care abroad, health care contacts of cases

Prevention Strategies: Back to the Basics







Hand Hygiene

Transmission-Based Precautions & Personal Protective Equipment

Environmental Cleaning & Disinfection

Disinfectants During COVID-19

- Many common disinfectants effective against COVID-19 are not effective against C. *auris*
 - especially products with only quaternary ammonium compounds
- List P: new list of EPA-approved disinfectants for C. auris
 - All are also effective against COVID-19



Infection Prevention Education




Project Firstline 1 **Project Firstline Home** Access Infection Control Educational Materials Project Firstline has created a new suite of educational materials and resources to help frontline healthcare workers, like you, understand and confidently apply the infection control actions necessary to protect your patients, yourselves, and your coworkers. Products range from bite-sized social media assets, to interactive scenarios, to toolkits for those interested in hosting their own infection control trainings. These resources were developed with healthcare workers, for healthcare workers - to ensure you receive infection control information you need and deserve in the learning format that's best for you. Videos and Social Interactive Resources ì Media Graphics ് Print Materials and **Training Toolkits** 9 9 9 Job Aids 2

https://www.cdc.gov/infectioncontrol/projectfirstline/healthcare/educational-materials.html#print

Page last reviewed: March 2, 2022

Coordinated Communication Between Facilities and Health Departments Is Critical To Prevent Spread




Facilities work together to protect patients.

Containment Strategies Before the First C. auris Case

- Assess infection control and ensure good IPC practices
- Use a disinfectant effective against C. auris
- Strengthen communication (interfacility and intrafacility) about *C. auris* for transferred patients/residents


Containment Steps After a Case of C. auris Is Found

- Report to the health department
- Infection control and staff education
- Screen patients with health care contact or high-risk patients/residents
- Lab surveillance
- Consider other connected facilities



Response Involves all Health Care

- Residents are shared across the health care continuum
- Communication is not always in place to ensure infection prevention measures are being used
- In health care settings, drugresistant organisms can be spread from person to person and between people and the environment
- Environmental cleaning, use of PPE, and good hand hygiene are some infection control measures that prevent transmission



ALFs/PCHs and C. auris



GEORGIA DEPARTMENT OF PUBLIC HEALTH

An Ounce of Prevention...

- Core Infection Prevention practices
 - Are current practices appropriate and consistent?
 - Are you assessing compliance?
- Check current disinfectant products
 - Do they have a kill claim for C. auris?
- Can you accept a C. *auris*-positive person?
 - Current CDC recommendations
- What should a C. *auris*-positive resident do before leaving their room?
 - Perform hand hygiene
 - Wear clean clothes
 - Cover wounds



- Share relevant infection control information with transport staff
- When receiving a resident, obtain relevant infection control information
 - Does the resident have a history of multi-drug resistant organism (MDRO) colonization or infection?

Resources

General:

- <u>https://www.cdc.gov/fungal/candida-auris/candida-auris-qanda.html</u>
- C. auris IPC guidance:
 - <u>https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html</u>
- C. auris fact sheets:
 - <u>https://www.cdc.gov/fungal/candida-auris/fact-</u> <u>sheets/index.html</u>
- C. auris tracking information:
 - <u>https://www.cdc.gov/fungal/candida-auris/tracking-</u> <u>c-auris.html</u>

Project Firstline infection prevention education:

 <u>https://www.cdc.gov/infectioncontrol/projectfirstline</u> /healthcare/educational-materials.html#print



Thank you!

https://www.cdc.gov/fungal/candida-auris


Candidaauris@cdc.gov

For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.



THINK FUNGUS. SAVE LIVES.



Thank you! Questions?

JoAnna M. Wagner, MSN, RN, BHSA, CIC

Director, Healthcare-Associated Infections Antimicrobial Resistance Program Georgia Department of Public Health Acute Disease and Epidemiology Section

200 Piedmont Avenue SE, 10th floor West Tower Atlanta, GA 30334

Mobile: (404) 430-6316 joanna.wagner@dph.ga.gov





Thank you! Consult with the DPH Team! We are here to help!

State Region/Districts	Contact Information
North (Rome, Dalton, Gainesville, Athens) Districts 1-1, 1-2, 2, 10	<u>Sue.bunnell@dph.ga.gov (404-967-0582)</u>
Atlanta Metro (Cobb-Douglas, Fulton, Clayton, Lawrenceville, DeKalb, LaGrange) Districts 3-1, 3-2, 3-3, 3-4, 3-5, 4	<u>Teresa.Fox@dph.ga.gov (256-293-9994)</u> <u>Renee.Miller@dph.ga.gov (678-357-4797)</u>
Central (Dublin, Macon, Augusta, & Columbus) Districts 5-1, 5-2, 6, 7	<u>Theresa.Metro-Lewis@dph.ga.gov (404-967-0589)</u> Karen.Williams13@dph.ga.gov (404-596-1732)
Southwest (Albany, Valdosta) Districts 8-1, 8-2	<u>Connie.Stanfill1@dph.ga.gov (404-596-1940)</u>
Southeast (Savannah, Waycross) Districts 9-1, 9-2	<u>Lynn.Reynolds@dph.ga.gov (804-514-8756)</u>
Backup/Nights/Weekends	Joanna.Wagner@dph.ga.gov (404-430-6316)



Alliant Health Solutions Resources



https://quality.allianthealth.org/topic/infection-control/



Thank You for Your Time! Contact the AHS Patient Safety Team <u>Patientsafety@allianthealth.org</u>



Amy Ward, MS, BSN, RN, CIC Patient Safety Manager <u>Amy.Ward@AlliantHealth.org</u> 678.527.3653



Paula St. Hill, MPH, A-IPC Technical Advisor, Infection Prevention <u>Paula.StHill@AlliantHealth.org</u> 678.527.3619



Donald Chitanda, MPH, CIC Technical Advisor, Infection Prevention Donald.Chitanda@AlliantHealth.org 678.527.3651



Erica Umeakunne, MSN, MPH, APRN, CIC Infection Prevention Specialist <u>Erica.Umeakunne@AlliantHealth.org</u>





Save the Date

SNF and Medical Directors Office Hours:

February 16, 2024 | 11 a.m. ET

ALF and PCH February 23, 2024 | 11 a.m. ET



Thank you!

- Georgia Department of Public Health
- University of Georgia





UNIVERSITY OF GEORGIA

Making Health Care Better





This material was prepared by Alliant Health Solutions, under contract with the Georgia Department of Public Health as made possible through the American Rescue Plan Act of 2021.

quality.allianthealth.org